Immunostep Launches Lyophilized Exosome Standards for Immune Diagnostics

In the rapidly advancing fields of biomedical research and clinical diagnostics, the ability to achieve high-precision detection and analysis of microscopic biomarkers remains a fundamental driver of technological innovation. Exosomes, the crucial messengers in intercellular communication, have emerged as a focal point for researchers due to their role in carrying biomolecular information, reflecting cellular states, and participating in disease progression. However, accurate and reliable quantification and characterization of exosomes require high-quality, standardized research tools. Addressing this need, Immunostep has introduced innovative lyophilized exosome standards, providing researchers with stable, convenient, and high-performance detection tools to accelerate exosome applications in disease diagnosis, prognosis assessment, and treatment monitoring.

Since its founding in 2001, Immunostep has been at the forefront of flow cytometry, developing cutting-edge reagents, kits, and solutions for applications in tumor immunology, hematology, stem cell research, immunology, and emerging exosome studies. The company's mission—"Empowering Precision Medicine, Driving Scientific Innovation"—reflects its commitment to integrating advanced technologies while maintaining rigorous quality standards. Through collaborations with global research institutions, Immunostep facilitates technology transfer and application, enhancing the efficiency of clinical research and diagnostic accuracy.

Recognizing the immense potential of exosomes in biomarker discovery and disease diagnostics, Immunostep established a dedicated exosome research team in 2017. The resulting ExoStep platform offers a complete workflow from sample processing to data analysis.

• Exosome Isolation Columns (SEC): Utilizing size-exclusion chromatography, these columns efficiently separate exosomes from various biofluids, including serum, plasma, urine, and saliva, while removing larger proteins and cellular debris.
• Exosome Capture Beads: Designed with specific antibodies or ligands, these beads enable efficient exosome capture for downstream immunological assays or quantitative analysis.
• Exosome Precipitation Solutions: A cost-effective method for rapid exosome isolation, suitable for large-scale studies, though additional purification may be required for high-purity applications.

This breakthrough innovation from Immunostep offers several advantages:

• Enhanced Stability: Lyophilization removes moisture, significantly improving long-term storage stability and preventing degradation during transport.
• Improved Convenience: The freeze-dried format simplifies experimental workflows, requiring only reconstitution before use.
• Standardization and Reproducibility: Rigorously quality-controlled standards provide reliable reference points for exosome quantification and cross-laboratory comparisons.

Immunostep offers a range of antibodies targeting exosome surface markers (e.g., CD63, CD9, CD81) for applications in immunofluorescence, flow cytometry, and immunoprecipitation.

Immunostep's immunology portfolio spans basic research to clinical diagnostics, including:

• Tumor Immunology and Hematology Antibodies: Monoclonal antibodies against tumor markers and immune cell surface molecules, pre-optimized multicolor flow panels (e.g., PNH, TBNK), and specialized kits for CAR-T cell analysis and stem cell characterization.
• Euroflow Standardized Reagents: Antibodies and multicolor panels compliant with Euroflow protocols, promoting global standardization in hematological and immunological flow cytometry.
• Immunology Antibodies: Crossmatch testing (FCXM) for transplantation, FcεR1 and Ig subclass antibodies for allergy research, and SARS-CoV-2-specific reagents.

Immunostep developed a suite of SARS-CoV-2 detection tools, including MPro assays, multiplex antigen tests, and Spike ELISA IgG kits, to aid in serological testing and vaccine research.

The company provides ancillary reagents (e.g., apoptosis detection kits, isotype controls) and comprehensive customization options, including peptide synthesis, protein services, and tailored exosome isolation protocols.

Operating under ISO 13485:2018 certification, Immunostep emphasizes continuous innovation, scientific rigor, and environmental responsibility. Its lyophilized exosome standards exemplify this commitment, offering researchers a transformative tool to unlock exosomes' potential in diagnostics and therapeutics.